Membrane localization of insulin receptor substrate-2 (IRS-2) is associated with decreased overall survival in breast cancer
dc.contributor.author | Clark, Jennifer L | |
dc.contributor.author | Dresser, Karen | |
dc.contributor.author | Hsieh, Chung-Cheng | |
dc.contributor.author | Sabel, Michael | |
dc.contributor.author | Kleer, Celina G | |
dc.contributor.author | Khan, Ashraf | |
dc.contributor.author | Shaw, Leslie M | |
dc.date.accessioned | 2023-05-08T14:40:05Z | |
dc.date.available | 2023-05-08T14:40:05Z | |
dc.date.issued | 2011-01-22 | |
dc.identifier.citation | Clark JL, Dresser K, Hsieh CC, Sabel M, Kleer CG, Khan A, Shaw LM. Membrane localization of insulin receptor substrate-2 (IRS-2) is associated with decreased overall survival in breast cancer. Breast Cancer Res Treat. 2011 Dec;130(3):759-72. doi: 10.1007/s10549-011-1353-1. Epub 2011 Jan 22. PMID: 21258861; PMCID: PMC3128655. | en_US |
dc.identifier.eissn | 1573-7217 | |
dc.identifier.doi | 10.1007/s10549-011-1353-1 | en_US |
dc.identifier.pmid | 21258861 | |
dc.identifier.uri | http://hdl.handle.net/20.500.14038/52039 | |
dc.description.abstract | Recent studies have identified a role for insulin receptor substrate-2 (IRS-2) in promoting motility and metastasis in breast cancer. However, no published studies to date have examined IRS-2 expression in human breast tumors. We examined IRS-2 expression by immunohistochemistry (IHC) in normal breast tissue, benign breast lesions, and malignant breast tumors from the institutional pathology archives and a tumor microarray from a separate institution. Three distinct IRS-2 staining patterns were noted: diffusely cytoplasmic, punctate cytoplasmic, and localized to the cell membrane. The individual and pooled datasets were analyzed for associations of IRS-2 staining pattern with core clinical parameters and clinical outcomes. Univariate analysis revealed a trend toward decreased overall survival (OS) with IRS-2 membrane staining, and this association became significant upon multivariate analysis (P = 0.01). In progesterone receptor negative (PR-) tumors, in particular, IRS-2 staining at the membrane correlated with significantly worse OS than other IRS-2 staining patterns (P < 0.001). When PR status and IRS-2 staining pattern were evaluated in combination, PR- tumors with IRS-2 at the membrane were associated with a significantly decreased OS when compared with all other combinations (P = 0.002). Evaluation of IRS-2 staining patterns could potentially be used to identify patients with PR- tumors who would most benefit from aggressive treatment. | en_US |
dc.language.iso | en | en_US |
dc.relation.ispartof | Breast Cancer Research and Treatment | en_US |
dc.relation.url | https://doi.org/10.1007/s10549-011-1353-1 | en_US |
dc.title | Membrane localization of insulin receptor substrate-2 (IRS-2) is associated with decreased overall survival in breast cancer | en_US |
dc.type | Journal Article | en_US |
dc.source.journaltitle | Breast cancer research and treatment | |
dc.source.volume | 130 | |
dc.source.issue | 3 | |
dc.source.beginpage | 759 | |
dc.source.endpage | 72 | |
dc.source.country | United States | |
dc.source.country | United States | |
dc.source.country | United States | |
dc.source.country | United States | |
dc.source.country | United States | |
dc.source.country | United States | |
dc.source.country | United States | |
dc.source.country | United States | |
dc.source.country | United States | |
dc.source.country | United States | |
dc.source.country | United States | |
dc.source.country | United States | |
dc.source.country | United States | |
dc.source.country | United States | |
dc.source.country | United States | |
dc.source.country | United States | |
dc.source.country | United States | |
dc.source.country | Netherlands | |
dc.identifier.journal | Breast cancer research and treatment | |
dc.contributor.department | Morningside Graduate School of Biomedical Sciences | en_US |
dc.contributor.department | T.H. Chan School of Medicine | en_US |
dc.contributor.student | Jennifer Clark | en_US |
dc.description.thesisprogram | MD/PhD | en_US |